2-ethylbenzylamine hydrochloride | 915395-32-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-ethylbenzylamine hydrochloride
• 英文别名: o-ethylbenzylamine hydrochloride；(2-Ethylphenyl)methylazanium;chloride
• CAS: 915395-32-3
• 化学式: C₉H₁₃N*ClH
• 分子量: 171.67
• InChiKey: BYLWFKPMPMYNQU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.13
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-ethylbenzylamine hydrochloride 、 二苯基氯化膦 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 14.1h， 以67%的产率得到
  参考文献：
  名称：

  [EN] SOLVENT, ADDITIVE AND CO-CATALYST EFFECTS FOR ETHYLENE OLIGOMERIZATION CATALYSIS
  [FR] EFFETS DE SOLVANT, D'ADDITIF ET DE COCATALYSEUR POUR LA CATALYSE PAR OLIGOMÉRISATION D'ÉTHYLÈNE

  摘要：

  这项发明涉及用于乙烯寡聚反应的催化剂系统。在某些实施例中，该催化剂系统包括乙烯、溶剂和与氧化铝烷共催化剂活化的催化剂。该系统还可以包括添加剂。可以对不同的反应参数进行各种修改，以微调反应性能，如产率、活性和对特定寡聚体的选择性。例如，溶剂可以修改为包含至少两种溶剂的混合物。另外，共催化剂可以通过老化或部分氟化来进行修改。在另一种替代方案中，可以在反应系统中加入添加剂。对反应系统的每次修改都会产生不同的反应结果，从而通过改变对反应系统的修改来微调反应性能。

  公开号：

  WO2009046144A1
• 作为产物：
  描述：

  2-乙基苯甲腈 、 盐酸 、 1,4-二氧六环 、 氢气 在 钯 作用下， 以 甲醇 为溶剂， 反应 48.0h， 以to provide 170A as a yellow solid (299 mg, 92%)的产率得到2-ethylbenzylamine hydrochloride
  参考文献：
  名称：

  Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants

  摘要：

  本发明提供了新型的苯基甘氨酰衍生物，其化学式为（I）或（IV）：或其立体异构体、互变异构体、药学上可接受的盐、溶剂化合物或前药，其中变量W、W1、Y、Z、R7、R8、R9和R11如定义所述。这些化合物是七号因子活化酶的选择性抑制剂，可用作药物。

  公开号：

  US20070003539A1

文献信息

• Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors
  申请人：Amberg Wilhelm

  公开号：US20100184787A1

  公开（公告）日：2010-07-22

  The invention relates to the hetaryl-substituted guanidine compounds of general formula (I), enantiomeres, diastereomeres and/or tautomeres thereof, in addition to the pharmaceutically acceptable salts thereof and the prodrugs of the known compounds. The invention also relates to the use of said hetaryl-substituted guanidine compounds as binding partners for 5-HT5-receptors for treating and/or for the prophylaxis of illnesses which are modulated by a 5-HT5-receptor activity, in particular, for treating and/or for the prophylaxis of neurodegenerative and neuropsychiatric disorders, and signs, symptoms and dysfunctions associated with said disorders.

  该发明涉及一般式(I)的杂环取代胍胺化合物，以及其对映体、非对映体和/或互变异构体，以及其药学上可接受的盐和已知化合物的前药。该发明还涉及将所述杂环取代胍胺化合物用作5-HT5受体的结合伙伴，用于治疗和/或预防由5-HT5受体活性调节的疾病，特别是用于治疗和/或预防神经退行性和神经精神障碍，以及与该类障碍相关的症状、体征和功能障碍。
• alpha-Aryl-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)benzeneacetonitriles
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP0170316A2

  公开（公告）日：1986-02-05

  Novel α-aryl-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)-benzeneacetontriles which are effective in destruting and/or preventing the growth of Protozoa; pharmaceutical compositions comprising such compounds as active ingredients and processes of preparing such compounds and pharmaceutical compositions.

  新型α-芳基-4-(4,5-二氢-3,5-二氧代-1,2,4-三嗪-2(3H)-基)-苯乙酰脞胺，可有效地去除和/或防止原生动物的生长；包含此类化合物作为活性成分的药物组合物，以及制备此类化合物和药物组合物的工艺。
• PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1910298A2

  公开（公告）日：2008-04-16
• SOLVENT, ADDITIVE AND CO-CATALYST EFFECTS FOR ETHYLENE OLIGOMERIZATION CATALYSIS
  申请人：Elowe Paul R.

  公开号：US20090118117A1

  公开（公告）日：2009-05-07

  The invention is directed to catalyst systems for the oligomerization of ethylene. In some embodiments, the catalyst system includes ethylene, a solvent, and a catalyst activated with an aluminoxane co-catalyst. The system may further include an additive. Various modifications to the different reaction parameters may be made to fine-tune the reaction properties, such as productivity, activity and selectivity for a particular oligomer. For example, the solvent may be modified to include a mixture of at least two solvents. Alternatively, the co-catalyst may be modified by aging or partially fluorinating the co-catalyst. In another alternative, an additive may be included in the reaction system. Each modification to the reaction system effects a different reaction outcome, thereby enabling fine-tuning of the reaction properties by varying the modifications to the reaction system.
• EMULSION COMPOSITION
  申请人：Yoneda Tadashi

  公开号：US20090252773A1

  公开（公告）日：2009-10-08

  An emulsion composition of the present invention includes (A) a salt of a higher fatty acid ester of ascorbic acid-2-phosphoric acid ester, (B) a polyglycerin fatty acid monoester including polyglycerin having a mean polymerization degree of 8 to 12 and an unsaturated fatty acid residual group of 14 to 22 carbon atoms, (C) a polyglycerin fatty acid monoester comprising polyglycerin having a mean polymerization degree of 2 to 6 and an unsaturated fatty acid residual group of 14 to 22 carbon atoms, and (D) a hydrocarbon oil, wherein the blending ratio by mass between the component (B) and the component (C) is in the range of 1:1 to 3:1, and the blending ratio by mass between the total of the components (B) and (C) and the component (D) is in the range of 10:1 to 1:4. By the use of the emulsion composition of the present invention, a skin external preparation can be provided which is prevented from decrease of a salt of a higher fatty acid ester of ascorbic acid-2-phosphoric acid ester attributable to decomposition of the salt, is excellent in retention of moisture, and has a beautiful appearance.